Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants

Pulmonology. 2024 Sep-Oct;30(5):485-487. doi: 10.1016/j.pulmoe.2024.03.001. Epub 2024 Apr 13.
No abstract available

Keywords: Cystic fibrosis; Elexacaftor-tezacaftor-ivacaftor; Non-F508del variants.

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aminophenols* / therapeutic use
  • Benzodioxoles* / therapeutic use
  • Cystic Fibrosis Transmembrane Conductance Regulator* / genetics
  • Cystic Fibrosis* / drug therapy
  • Drug Combinations*
  • Female
  • Humans
  • Indoles* / therapeutic use
  • Male
  • Portugal / epidemiology
  • Pyrazoles / therapeutic use
  • Pyridines / therapeutic use
  • Pyrroles / therapeutic use
  • Pyrrolidines
  • Quinolines / therapeutic use
  • Quinolones* / therapeutic use
  • Treatment Outcome
  • Young Adult

Substances

  • Benzodioxoles
  • Aminophenols
  • Quinolones
  • Drug Combinations
  • Indoles
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Pyrazoles
  • Pyridines
  • Pyrroles
  • Quinolines
  • elexacaftor, ivacaftor, tezacaftor drug combination
  • elexacaftor
  • tezacaftor
  • CFTR protein, human
  • Pyrrolidines